Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
150.4 USD | +1.36% | +0.26% | -21.40% |
Financials (USD)
Sales 2024 * | 1.87B | Sales 2025 * | 2.26B | Capitalization | 18.78B |
---|---|---|---|---|---|
Net income 2024 * | -451M | Net income 2025 * | -257M | EV / Sales 2024 * | 9.43 x |
Net cash position 2024 * | 1.13B | Net cash position 2025 * | 443M | EV / Sales 2025 * | 8.11 x |
P/E ratio 2024 * |
-42
x | P/E ratio 2025 * |
-79.7
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | -1.06% | ||
1 week | +0.45% | ||
1 month | -1.25% | ||
3 months | -2.74% | ||
6 months | -13.41% | ||
Current year | -22.45% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
5.08% | 1 M€ | -.--% | - | |
4.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 150.4 | +1.36% | 856 177 |
24-05-31 | 148.4 | -1.07% | 1,250,341 |
24-05-30 | 150 | +2.11% | 655,697 |
24-05-29 | 146.9 | -2.09% | 875,955 |
24-05-28 | 150.1 | +1.56% | 510,344 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.45% | 18.78B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B | |
-3.38% | 9.6B |
- Stock Market
- Equities
- ALNY Stock